Prostate CancerLutetiumBACKGROUND Lutetium has been shown to be an important potential innovation in pre-treated metastatic castration-resistant prostate cancer.Two clinical trials have evaluated lutetium thus far(therap and vision with 99 and 385 patients,respectively),but their results are discordant....
Lutetium Lu 177 vipivotide tetraxetan is a radioligand that strongly binds to PSMA, making it ideal for treating cancers of the prostate by targeted radiation, resulting in DNA damage and cell death. PSMA is overexpressed in cancer cells while being lowly expressed in normal tissues, which makes...
Treatment with lutetium-PSMA is based on the ability of PSMA ligand that is labeled with the radioisotope 177-lutetium to bind specifically to PSMA-expressing prostate cancer cells to cause cellular damage. Recently, the efficacy of lutetium PSMA has been demonstrated in castrate-resistant metastatic ...
23, 2022, the FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto; Novartis), which is referred to in nuclear medicine literature as 177Lu–prostate-specific membrane antigen–617 (177Lu PSMA-617), for the treatment of PSMA-positive metastatic castration resistant p...
1. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. [J] . Patel H, Mick R, Finlay J, Clinical cancer research: an official journal of the American Association for Cancer Research . 2008 ,第15期 机译:Motexafin et光动力...
Initial studies have shown promising results with Lutetium-177 prostate-specific membrane antigen (Lu-177-PSMA) therapy for advanced prostate cancer. However,... A Parveen,A Fatima,IKIUSA Fatima - 《Nuclear Medicine Communications》 被引量: 0发表: 2023年 Clinical Variables Associated with PSA Respo...
Dose given to the prostate and each surrounding organ is obtained for both treatments. • Results have been verified with doses calculated by deterministic planning system. Abstract Radiation Therapy Planning Systems (RTPS) presently operating in hospitals comprise algorithms founded on deterministic simp...
1 other channel Advanced Prostate Cancer Expert Opinion / Interview · March 15, 2022 Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Interview with Oliver Sartor MD Save Recommend Share Facebook Twitter LinkedIn Print Email × You must be a m...
Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: population-based data with multicenter validation from 2016 to 2020 喜欢 0 阅读量: 10 作者: L Flegar,S Thoduka,D Librizzi,M Luster,A Zacharis,H Heers,N Eisenmenger,H Ahmadzadehfar,M Eiber,...
Phase I Trial of Motexafin Lutetium-Mediated Interstitial Photodynamic Therapy in Patients with Locally Recurrent Prostate Cancer Therapeutic options for patients with locally recurrent prostate cancer after treatment with radiation therapy are limited. An ongoing Phase I trial of int... DCH Stripp,R ...